Advances in Immunotherapy for Malignant Pleural Mesothelioma: From Emerging Strategies to Translational Insights

Our plain-English summary of Advances in Immunotherapy for Malignant Pleural Mesothelioma: From Emerging Strategies to Translational Insights, by R. López-Castro, Á. Fuentes-Martín, A. Medina Del Valle, et al (Open Respiratory Archives, 2024).

The study

• Authors: R. López-Castro, Á. Fuentes-Martín, A. Medina Del Valle, T. García Peña, J. Soro García, L. López González, Á. Cilleruelo Ramos
• Journal: Open Respiratory Archives
• Published: 2024;6(3):100323
• Type of article: Review
• Cited by: 8 articles, as counted by NIH iCite
• Read it: PubMed · Publisher · Free full text

Abstract

MPM stands as a rare malignancy necessitating improved therapeutic strategies due to its limited treatment choices and unfavorable prognosis. The advent of immune checkpoint inhibitors has heralded a paradigm shift in the therapeutic landscape of MPM, offering promising avenues across diverse clinical scenarios. In the context of advanced stages of the disease, Immune check-point inhibitors targeting programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte-as-sociated protein 4 (CTLA-4), have exhibited encouraging potential in clinical trials, particularly manifesting efficacy among patients exhibiting disease progression following chemotherapy regimens. Innovative combination regimens, exemplified by the concurrent administration of nivolumab and ipilimumab, have demonstrated marked improvement in survival and patient's benefits. A deeper comprehension of the intricate genetic underpinnings of MPM, encompassing key mutations such as cyclin-dependent kinase inhibitor 2A (CDKN2A), neurofibromin 2 (NF2), and BRCA1-associated protein 1 (BAP1) mutations, has elucidated novel avenues for targeted therapeutic interventions. This review accentuates the transformative capacity of immunotherapy in revolutionizing the therapeutic outlook for MPM, thereby potentially translating into augmented survival rates and offering glimpses of new approaches on the horizon. Despite the persisting challenges, the synergistic crossroads of interdisciplinary research and collaborative clinical endeavors portend a hopeful landscape for MPM treatment.

© 2024 Sociedad Española de Neumología y Cirugía Torácica (SEPAR). Published by Elsevier España, S.L.U.

In plain English

This article is a narrative review, not a new study. The authors, based in Valladolid, Spain, summarized published clinical trials of immune checkpoint inhibitor drugs for malignant pleural mesothelioma. They also gave background on the disease's genetics (CDKN2A, NF2 and BAP1) and on emerging approaches such as CAR T cells, oncolytic viruses, WT1 vaccines and microRNAs. They did not describe how studies were chosen. Among the trials reviewed, CheckMate 743 reported median overall survival of 18.1 months with first-line nivolumab plus ipilimumab versus 14.1 months with platinum-pemetrexed chemotherapy (hazard ratio 0.74, 95% confidence interval 0.60 to 0.91). In previously treated patients, the CONFIRM trial reported median overall survival of 10.2 months with nivolumab versus 6.9 months with placebo. The PROMISE-meso pembrolizumab trial did not meet its primary endpoint, and in the DETERMINE study tremelimumab did not significantly improve survival over placebo. The authors concluded that immunotherapy has potential as a cornerstone of mesothelioma management, while further research on predictive biomarkers and resistance mechanisms is needed. The review did not study asbestos exposure.

We wrote this plain-English summary from the full article with the help of AI, and a second AI model checked each sentence against the article. It is not the authors' wording; the abstract and the article are their own account.

What the study did and found

• Design: Narrative review of published clinical trials and laboratory research on immunotherapy for malignant pleural mesothelioma; no search or selection methods are described
• Who was studied: No new patients were studied. The review covered published and ongoing clinical trials of immune checkpoint inhibitors in malignant pleural mesothelioma (MPM): second-line and later treatment, first-line treatment, and adjuvant treatment after surgery.
• Exposure: Not an asbestos exposure study. The treatments reviewed were immune checkpoint inhibitors: nivolumab, ipilimumab, pembrolizumab, tremelimumab, avelumab, durvalumab and atezolizumab, alone, combined with each other, or combined with chemotherapy. Asbestos is mentioned only as background, and no fiber types are specified.
• Main results:
  • CheckMate 743 trial (reviewed, first-line treatment): median overall survival was 18.1 months with nivolumab plus ipilimumab versus 14.1 months with platinum-pemetrexed chemotherapy, hazard ratio 0.74 (95% CI 0.60 to 0.91)
  • CONFIRM trial (reviewed, previously treated patients): median overall survival was 10.2 months with nivolumab versus 6.9 months with placebo, HR 0.69
  • PROMISE-meso phase III trial (reviewed): pembrolizumab compared with chemotherapy in 144 previously treated patients did not meet its primary endpoint of progression-free survival
  • DETERMINE study (reviewed): tremelimumab did not significantly improve overall survival compared with placebo
  • IND.227 phase III trial (reviewed, 440 previously untreated patients): adding pembrolizumab to chemotherapy gave an overall survival benefit, HR 0.79 (95% CI 0.64 to 0.98, p = 0.0324), with a modest numerical difference in median survival of 17.28 versus 16.13 months
  • Meta-analysis (reviewed) of 13 studies with 888 patients treated with anti-PD-1 or anti-PD-L1 drugs after earlier treatment: overall response rate was 18.1% (95% CI 13.9 to 22.8%) and disease control rate was 55.4% (95% CI 48.1 to 62.5%)
• The authors' conclusion: The authors concluded that immune checkpoint inhibitors have improved survival outcomes and that immunotherapy has potential as a cornerstone in managing MPM, while further investigation of predictive biomarkers and resistance mechanisms is needed.

Topics

Medical terms in this study, explained in our Lexicon: Immunotherapy, Pleural Mesothelioma, Prognosis, checkpoint inhibitors, CTLA-4, Clinical Trial, Disease Progression, Chemotherapy.

Related studies

• Immunotherapy for Treatment of Pleural Mesothelioma: Current and Emerging Therapeutic Strategies — L. Chiec, D.S. Bruno (2024)
• The development and deployment of Common Data Elements for tissue banks for translational research in cancer - an emerging standard based approach for the Mesothelioma Virtual Tissue Bank — S.K. Mohanty, A.T. Mistry, et al. (2008)
• Emerging translational therapies for mesothelioma — H.I. Pass, B.W. Robinson, et al. (1999)
• Translational advances in pleural malignancies — G.T. Stathopoulos (2011)
• Telomeres and telomerase in mesothelioma: Pathophysiology, biomarkers and emerging therapeutic strategies (Review) — D. Andreikos, D.A. Spandidos, et al. (2025)
• From biology to therapy: current standards and emerging strategies in pleural mesothelioma — J.H.L.T. van Genugten, C.J. de Gooijer, et al. (2026)

Browse return to medical research.